Three experimental injectable antiretrovirals – a novel capsid inhibitor and two next-generation integrase inhibitors – could ...

AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety of risankizumab (SKYRIZI®) ...

RHHBY says the ZUPREME-1 study meets its goal as petrelintide delivers up to 10.7% weight loss with placebo-like tolerability ...

Local lidocaine injection shows a similar early anesthetic effect in adults with Ehlers-Danlos syndrome and healthy ...

Roche Group AG’s RHHBY obesity drug push faces stiff competition after Genentech, a unit of Roche, reported Phase 2 results ...

A new study finds that GLP-1 drugs may help to stabilize chronic migraines, with patients seeing fewer ER visits and less ...

Touted by some as a miracle cure-all, stacking is attracting attention for another reason, too: a lack of long-term data and ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Ascendis Pharma’s Yuviwel (navepegritide) for ...

Highly publicized growth trajectories of some of the biggest companies out there may make it seem like 2026 is not a prime ...

Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-valueAt the maximally effective dose, there were no cases of vomiting and no treatment ...

Xeris Biopharma benefits from the FDA's CRL to Corcept's relacorilant, removing a major competitive threat to Recorlev sales ...

Efgartigimod alfa–hyaluronidase significantly improves ocular symptoms in adults with ocular myasthenia gravis, according to phase 3 trial data.